A Study to Assess the Safety and Effectiveness of Durogesic (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Long-term Narcotic Pain Relief Therapy
Chronic Pain
About this trial
This is an interventional treatment trial for Chronic Pain focused on measuring chronic pain, opioid, fentanyl, transdermal, Durogesic, morphine
Eligibility Criteria
Inclusion Criteria: Patients with a confirmed malignancy (whose pain is judged by the investigator to be caused by the malignancy), or patients with other life-threatening/terminal disease whose pain requires treatment with strong opioid analgesia requiring treatment of pain with a strong opioid and who are expected to continue to require treatment with a strong opioid for the duration of the study receiving a stable dose of immediate-release oral morphine or sustained-release morphine (minimum daily dose of morphine is 30 mg/day) for at least 48 hours immediately prior to entry into the study Exclusion Criteria: Patients with a history of allergy or hypersensitivity to fentanyl or morphine have active skin disease that precludes application of Durogesic® or which may affect the absorption of fentanyl have a clinical condition that in the investigator's judgment prevents participation in the study have participated in any other drug trial relating to pain control within one month of study entry currently participating in any other study or research project which would interfere with this trial.